Both the ATTRACTION-4 and ORIENT-16 trial results overall support the efficacy of the addition of immunotherapy to first line platinum-based chemotherapy in advanced gastric cancer patients as a new standard of care, with most of the benefit seen in PD-L1 CPS positive disease. The gene discussed is CD274; the disease is gastric cancer.